Gastrointestinal absorption of aluminum is increased in Down'ssyndrome
P.B. Moore
Bok Engelsk 1997
| Utgitt | 1997
|
|---|---|
| Omfang | Side 488- 492
|
| Opplysninger | Individuals with Down's Syndrome (DS) develop the neuropathologicalfeatures of senile dementia of the Alzheimer's type (SDAT) by earlymiddle age. Because of recent evidence that gastrointestinal (GI)aluminum (Al) absorption is increased in patients with SDAT, and thatAl may contribute to associated neuropathological changes, we haveinvestigated the GI uptake of Al in patients with DS by two methods.The first measured the absorption of Al-27 at concentrationsassociated with antacid use, in the presence of citrate, using atomicabsorption spectrometry. There was no difference between basal bloodconcentrations of Al-27 in 15 DS subjects (36-46 years) and 15 age-matched controls. The mean increase in Al-27 blood concentrations 60minutes after the dose of Al was four times greater in the DS groupthan in controls (p < 0.001). The second measured GI absorption of Al-26 under normal dietary conditions using accelerator massspectrometry. With Al-26 the mean Al absorption in DS subjects (n =5) exceeded that of controls (n = 4) by a factor of 6 (p < 0.02).Although the mechanisms of enhanced absorption are unknown, the dataindicate that similar abnormalities in the GI handling of Al occur inboth SDAT and DS suggesting that it may be advisable to minimizedietary exposure to Al in subjects at risk of developing Alzheimer-type pathology. (C) 1997 Society of Biological Psychiatry.
|
| Emner |
